Headquartered in Gaithersburg, Maryland, Novavax is a biotechnology firm that focuses on the invention, improvement and commercialisation of vaccines to forestall infectious ailments.
Throughout his discussions with Stanley C Erck, President, Chief Government Officer & Director at Novavax, Sandhu mentioned the partnership between Novavax and SII is one other instance of the “sturdy India-US healthcare cooperation”, particularly within the manufacturing of inexpensive and accessible vaccines and medicines.
Erck briefed the ambassador on the excessive efficacy of the COVID-19 vaccine as per trials held thus far. In January 2020, Novavax introduced improvement of a coronavirus vaccine candidate. Subsequently Novavax and India’s SII had entered right into a vaccine manufacture settlement with the Novovax vaccine anticipated to be distributed as ‘Covavax’ in India.
On June 14, Novavax had introduced total 90.4 per cent efficacy in Part-3 trials in US and Mexico.
Sandhu famous that healthcare sectors in each international locations have been collaborating by means of joint analysis, sharing of technical experience and data trade.
The Indian envoy has reached out to numerous pharma corporations within the US. His outreach to vaccine producers/companies within the vaccine provide chain embody Pfizer, Modern, Johnson & Johnson, Air Merchandise, AdvaMed, Thermo Fisher, Eli Lilly, Pall Company, Antylia, Cytiva, Genentech, Ligand, and so on.
Earlier this month, he had additionally visited Occugen and Jubilant Pharma amenities.
Based in 1987, Novavax operates by means of creating recombinant vaccines. The corporate, by means of its recombinant nanoparticle vaccine expertise, produces vaccine candidates to reply to each identified and newly rising ailments.
Its product pipeline focuses on a spread of infectious ailments with vaccine candidates in scientific improvement for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus.